Peter Kolchinsky portfolio, Q1 2026
RA Capital Management · 13F for the quarter ending Mar 31, 2026
For Q1 2026, RA Capital Management reported $9.4B across 85 US-listed positions, led by ASND (24.9%), PCVX (7.1%) and RYTM (6.1%). Compared with its filing for Q4 2025, Peter Kolchinsky opened 24 new positions, added to 17, reduced 2 and sold out of 10; 42 positions did not change.
The largest purchase was a new position in SGP ($207.8M); the largest sale, the sale of the whole position in Cidara Therapeutics Inc ($743.4M).
Key facts
- 13F portfolio value
- $9.4BQ1 2026
- Positions
- 85
- Largest holding
- ASND 24.9%
- New positions
- 24
- Sold out
- 10
- Filed
- May 15, 2026
Holdings as of (Q1 2026), filed with the SEC on . Changes are measured against the filing for Dec 31, 2025. Every tracked investor's Q1 2026 13F.
Bought and sold in Q1 2026
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
Cidara Therapeutics Incno ticker on file | ▼ Sold out | −3.37M | $743.4M | 7.88% |
Avidity Biosciences Incno ticker on file | ▼ Sold out | −8.64M | $623.3M | 6.60% |
| Spyglass Pharma IncSGP | ▲ New | +8.02M | $207.8M | 2.20% |
| Zai Lab LtdZLAB | ▲ New | +5.71M | $107.4M | 1.14% |
| Sarepta Therapeutics IncSRPT | ▲ New | +3.9M | $84.9M | 0.90% |
| Dianthus Therapeutics IncDNTH | ▲ Added 62% | +1M | $83.9M | 0.89% |
Arcellx Incno ticker on file | ▼ Sold out | −1.27M | $82.6M | 0.88% |
| Belite Bio IncBLTE | ▼ Sold out | −432.48K | $69.2M | 0.73% |
Nuvalent Incno ticker on file | ▲ Added 35% | +654.09K | $67M | 0.71% |
| Wave Life Sciences LtdWVE | ▲ Added 48% | +8.77M | $63.6M | 0.67% |
| Damora Therapeutics IncDMRA | ▲ New | +2.4M | $62.1M | 0.66% |
| Xencor IncXNCR | ▲ New | +4.9M | $59.1M | 0.63% |
| Vaxcyte IncPCVX | ▲ Added 7.0% | +750K | $43.6M | 0.46% |
| Invivyd IncIVVD | ▼ Sold out | −17.12M | $42.3M | 0.45% |
| Century Therapeutics IncIPSC | ▲ New | +17.75M | $40.1M | 0.43% |
| Disc Medicine IncIRON | ▲ Added 24% | +474.09K | $30.3M | 0.32% |
| Mirum Pharmaceuticals IncMIRM | ▲ New | +318.55K | $29.4M | 0.31% |
| Bioage Labs IncBIOA | ▲ New | +1.65M | $28.9M | 0.31% |
| Aktis Oncology IncAKTS | ▲ New | +1.5M | $26.9M | 0.28% |
| Alx Oncology Holdings IncALXO | ▲ New | +13.01M | $26.1M | 0.28% |
| Aclaris Therapeutics IncACRS | ▲ New | +6.8M | $25.5M | 0.27% |
| Solid Biosciences IncSLDB | ▲ Added 61% | +3.53M | $25.4M | 0.27% |
| Travere Therapeutics IncTVTX | ▲ New | +746.84K | $22.2M | 0.24% |
| Relmada Therapeutics IncRLMD | ▲ New | +2.95M | $20.5M | 0.22% |
| Bright Minds Biosciences IncDRUG | ▲ New | +265K | $19.3M | 0.20% |
| Sutro Biopharma IncSTRO | ▲ New | +715.31K | $17.8M | 0.19% |
| Anteris Technologies GlobalAVR | ▲ New | +3M | $16.7M | 0.18% |
| Onkure Therapeutics Inc-AOKUR | ▲ New | +4M | $16.6M | 0.18% |
| Design Therapeutics IncDSGN | ▲ Added 103% | +1.51M | $16.1M | 0.17% |
| Acumen Pharmaceuticals IncABOS | ▲ Added 41% | +6.06M | $14.3M | 0.15% |
| Medline IncMDLN | ▼ Sold out | −335K | $14.1M | 0.15% |
| Helix Acquisition CorpHLXC | ▲ New | +1.25M | $12.7M | 0.13% |
| Atrium Therapeutics IncRNA | ▲ New | +864.1K | $11.6M | 0.12% |
| Contineum Therapeutics IncCTNM | ▼ Reduced 41% | −883.7K | $11.5M | 0.12% |
| Hinge Health IncHNGE | ▲ Added 355% | +284.5K | $11M | 0.12% |
| Karyopharm Therapeutics IncKPTI | ▲ New | +1.92M | $10.7M | 0.11% |
| Mineralys Therapeutics IncMLYS | ▲ Added 5.0% | +369K | $10M | 0.11% |
| GeneDx Holdings CorpWGS | ▲ Added 262% | +151.84K | $9.8M | 0.10% |
| Inspire Med Systems IncINSP | ▲ Added 129% | +183.7K | $9.5M | 0.10% |
| Waystar Holding CorpWAY | ▲ Added 267% | +385K | $9.3M | 0.10% |
| Corvus Pharmaceuticals IncCRVS | ▲ New | +450K | $6.6M | 0.07% |
| Equillium IncEQ | ▲ New | +3.1M | $6.2M | 0.07% |
| Bicara Therapeutics IncBCAX | ▲ Added 4.3% | +300K | $6M | 0.06% |
| 4D Molecular TherapeuticsFDMT | ▼ Reduced 11% | −603.43K | $5.6M | 0.06% |
| Macrogenics IncMGNX | ▲ New | +1.86M | $5.4M | 0.06% |
| Maplight Therapeutics IncMPLT | ▲ New | +248.29K | $5M | 0.05% |
| Progyny IncPGNY | ▼ Sold out | −96.63K | $2.5M | 0.03% |
| Qiagen NVQGEN | ▼ Sold out | −43.98K | $2.1M | 0.02% |
| Orthopediatrics CorpKIDS | ▼ Sold out | −109.96K | $2M | 0.02% |
| Health Catalyst IncHCAT | ▼ Sold out | −793.75K | $1.9M | 0.02% |
| Adicet Bio IncACET | ▲ Added 25% | +234.38K | $1.6M | 0.02% |
| Evommune IncEVMN | ▲ Added 1.0% | +35.87K | $824.6K | 0.01% |
| Climb Bio IncCLYM | ▲ Added 0.06% | +7.11K | $48.7K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q4 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 24.9% | $2.4B | 10.28M | $228.73 | 8+ qtrs | No change |
| 2 | Vaxcyte IncPCVX | Health Care | 7.07% | $666.8M | 11.47M | $58.11 | 8+ qtrs | ▲ Added 7.0% |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 6.14% | $579.8M | 6.67M | $86.97 | 8+ qtrs | No change |
| 4 | Tyra Biosciences IncTYRA | — | 4.95% | $467.2M | 12.2M | $38.30 | 8+ qtrs | No change |
| 5 | Sionna Therapeutics IncSION | — | 4.21% | $397.1M | 9.91M | $40.09 | 5 qtrs | No change |
| 6 | Edgewise Therapeutics IncEWTX | Health Care | 3.48% | $328.5M | 10.43M | $31.50 | 8+ qtrs | No change |
| 7 | Newamsterdam Pharma CompanyNAMS | — | 3.24% | $305.7M | 9.55M | $32.01 | 8+ qtrs | No change |
| 8 | Nuvalent Incno ticker on file | — | 2.75% | $259.6M | 2.53M | $102.45 | 3 qtrs | ▲ Added 35% |
| 9 | Dianthus Therapeutics IncDNTH | Health Care | 2.32% | $219.2M | 2.61M | $83.92 | 8+ qtrs | ▲ Added 62% |
| 10 | Mineralys Therapeutics IncMLYS | — | 2.21% | $208.4M | 7.69M | $27.09 | 8+ qtrs | ▲ Added 5.0% |
| 11 | Spyglass Pharma IncSGP | — | 2.20% | $207.8M | 8.02M | $25.91 | 1 qtr | New |
| 12 | Wave Life Sciences LtdWVE | — | 2.07% | $195.6M | 26.98M | $7.25 | 8+ qtrs | ▲ Added 48% |
| 13 | Septerna IncSEPN | — | 1.78% | $168.1M | 7M | $24.03 | 6 qtrs | No change |
| 14 | Disc Medicine IncIRON | — | 1.66% | $156.7M | 2.45M | $63.94 | 5 qtrs | ▲ Added 24% |
| 15 | Janux Therapeutics IncJANX | — | 1.65% | $155.5M | 11.19M | $13.90 | 8+ qtrs | No change |
| 16 | BioCryst Pharmaceuticals IncBCRX | — | 1.60% | $150.7M | 15.83M | $9.52 | 2 qtrs | No change |
| 17 | Bicara Therapeutics IncBCAX | — | 1.53% | $144.3M | 7.26M | $19.89 | 7 qtrs | ▲ Added 4.3% |
| 18 | Praxis Precision MedicinesPRAX | Health Care | 1.28% | $120.4M | 373.79K | $322.19 | 2 qtrs | No change |
| 19 | GH Research PLCGHRS | — | 1.14% | $107.9M | 7.68M | $14.06 | 8+ qtrs | No change |
| 20 | Zai Lab LtdZLAB · ADR | — | 1.14% | $107.4M | 5.71M | $18.81 | 1 qtr | New |
| 21 | Taysha Gene Therapies IncTSHA | — | 1.12% | $105.3M | 23.56M | $4.47 | 8+ qtrs | No change |
| 22 | Vor Biopharma IncVOR | — | 1.02% | $96.4M | 5.4M | $17.84 | 8+ qtrs | No change |
| 23 | Geron CorpGERN | — | 1.01% | $95M | 63.77M | $1.49 | 8+ qtrs | No change |
| 24 | Ars Pharmaceuticals IncSPRY | — | 0.92% | $87.2M | 10.86M | $8.03 | 8+ qtrs | No change |
| 25 | Sarepta Therapeutics IncSRPT | — | 0.90% | $84.9M | 3.9M | $21.76 | 1 qtr | New |
| 26 | Spyre Therapeutics IncSYRE | Health Care | 0.87% | $81.8M | 1.62M | $50.44 | 2 qtrs | No change |
| 27 | Evommune IncEVMN | — | 0.85% | $80.3M | 3.49M | $22.99 | 2 qtrs | ▲ Added 1.0% |
| 28 | Climb Bio IncCLYM | — | 0.82% | $77.4M | 11.3M | $6.85 | 8+ qtrs | ▲ Added 0.06% |
| 29 | Solid Biosciences IncSLDB | — | 0.71% | $67.2M | 9.34M | $7.20 | 8+ qtrs | ▲ Added 61% |
| 30 | Artiva Biotherapeutics IncARTV | — | 0.67% | $63.5M | 9.85M | $6.44 | 7 qtrs | No change |
| 31 | Damora Therapeutics IncDMRA | — | 0.66% | $62.1M | 2.4M | $25.90 | 1 qtr | New |
| 32 | Xencor IncXNCR | — | 0.63% | $59.1M | 4.9M | $12.06 | 1 qtr | New |
| 33 | LB Pharmaceuticals IncLBRX | — | 0.58% | $54.5M | 2.21M | $24.66 | 3 qtrs | No change |
| 34 | Jade Biosciences IncJBIO | — | 0.55% | $51.6M | 3.67M | $14.05 | 4 qtrs | No change |
| 35 | Acumen Pharmaceuticals IncABOS | — | 0.53% | $49.5M | 20.99M | $2.36 | 8+ qtrs | ▲ Added 41% |
| 36 | 4D Molecular TherapeuticsFDMT | — | 0.50% | $47M | 5.05M | $9.31 | 8+ qtrs | ▼ Reduced 11% |
| 37 | Fulcrum Therapeutics IncFULC | — | 0.49% | $46.4M | 6.05M | $7.67 | 8+ qtrs | No change |
| 38 | Capricor Therapeutics IncCAPR | — | 0.49% | $45.8M | 1.51M | $30.40 | 2 qtrs | No change |
| 39 | Century Therapeutics IncIPSC | — | 0.43% | $40.1M | 17.75M | $2.26 | 1 qtr | New |
| 40 | Olema Pharmaceuticals IncOLMA | — | 0.41% | $38.8M | 2.6M | $14.91 | 2 qtrs | No change |
| 41 | Lenz Therapeutics IncLENZ | — | 0.41% | $38.2M | 4.18M | $9.15 | 8+ qtrs | No change |
| 42 | Monopar Therapeutics IncMNPR | — | 0.39% | $36.6M | 667.21K | $54.79 | 6 qtrs | No change |
| 43 | Pepgen IncPEPG | — | 0.38% | $35.5M | 20.06M | $1.77 | 8+ qtrs | No change |
| 44 | Design Therapeutics IncDSGN | — | 0.34% | $31.6M | 2.97M | $10.64 | 3 qtrs | ▲ Added 103% |
| 45 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.31% | $29.4M | 318.55K | $92.38 | 1 qtr | New |
| 46 | Bioage Labs IncBIOA | — | 0.31% | $28.9M | 1.65M | $17.49 | 1 qtr | New |
| 47 | Lexeo Therapeutics IncLXEO | — | 0.30% | $28.7M | 5M | $5.74 | 2 qtrs | No change |
| 48 | Assembly Biosciences IncASMB | — | 0.30% | $28.3M | 1.02M | $27.75 | 3 qtrs | No change |
| 49 | Rezolute IncRZLT | — | 0.30% | $28M | 9.18M | $3.05 | 2 qtrs | No change |
| 50 | Aktis Oncology IncAKTS | — | 0.29% | $26.9M | 1.5M | $17.89 | 1 qtr | New |
| 51 | Alx Oncology Holdings IncALXO | — | 0.28% | $26.1M | 13.01M | $2.00 | 1 qtr | New |
| 52 | Aclaris Therapeutics IncACRS | — | 0.27% | $25.5M | 6.8M | $3.75 | 1 qtr | New |
| 53 | Ovid Therapeutics IncOVID | — | 0.25% | $23.8M | 10.71M | $2.22 | 2 qtrs | No change |
| 54 | Nkarta IncNKTX | — | 0.24% | $22.8M | 10.81M | $2.11 | 8+ qtrs | No change |
| 55 | Travere Therapeutics IncTVTX | Health Care | 0.24% | $22.2M | 746.84K | $29.71 | 1 qtr | New |
| 56 | Grail IncGRAL | Health Care | 0.24% | $22.1M | 428.27K | $51.68 | 2 qtrs | No change |
| 57 | C4 Therapeutics IncCCCC | — | 0.22% | $21M | 8M | $2.63 | 2 qtrs | No change |
| 58 | Relmada Therapeutics IncRLMD | — | 0.22% | $20.5M | 2.95M | $6.96 | 1 qtr | New |
| 59 | Benitec Biopharma IncBNTC | — | 0.21% | $19.7M | 1.85M | $10.65 | 2 qtrs | No change |
| 60 | Bright Minds Biosciences IncDRUG | — | 0.21% | $19.3M | 265K | $72.97 | 1 qtr | New |
| 61 | Sutro Biopharma IncSTRO | — | 0.19% | $17.8M | 715.31K | $24.91 | 1 qtr | New |
| 62 | Contineum Therapeutics IncCTNM | — | 0.18% | $16.9M | 1.3M | $13.06 | 3 qtrs | ▼ Reduced 41% |
| 63 | Sab Biotherapeutics IncSABS | — | 0.18% | $16.9M | 4.4M | $3.83 | 3 qtrs | No change |
| 64 | Inspire Med Systems IncINSP | — | 0.18% | $16.8M | 325.66K | $51.58 | 3 qtrs | ▲ Added 129% |
| 65 | Anteris Technologies GlobalAVR | — | 0.18% | $16.7M | 3M | $5.55 | 1 qtr | New |
| 66 | Onkure Therapeutics Inc-AOKUR | — | 0.18% | $16.6M | 4M | $4.14 | 1 qtr | New |
| 67 | Hinge Health IncHNGE | Technology | 0.15% | $14.1M | 364.61K | $38.56 | 2 qtrs | ▲ Added 355% |
| 68 | GeneDx Holdings CorpWGS | — | 0.14% | $13.5M | 209.89K | $64.22 | 4 qtrs | ▲ Added 262% |
| 69 | Waystar Holding CorpWAY | Technology | 0.14% | $12.8M | 529.4K | $24.11 | 2 qtrs | ▲ Added 267% |
| 70 | Helix Acquisition CorpHLXC | — | 0.14% | $12.7M | 1.25M | $10.16 | 1 qtr | New |
| 71 | Palisade Bio IncPALI | — | 0.13% | $12.5M | 7.12M | $1.75 | 2 qtrs | No change |
| 72 | Acrivon Therapeutics IncACRV | — | 0.12% | $11.6M | 8.34M | $1.39 | 8+ qtrs | No change |
| 73 | Atrium Therapeutics IncRNA | — | 0.12% | $11.6M | 864.1K | $13.37 | 1 qtr | New |
| 74 | Karyopharm Therapeutics IncKPTI | — | 0.11% | $10.7M | 1.92M | $5.57 | 1 qtr | New |
| 75 | Avalo Therapeutics IncAVTX | — | 0.11% | $9.9M | 662.97K | $14.93 | 7 qtrs | No change |
| 76 | Perceptive Cap Solutionsno ticker on file | — | 0.09% | $8.2M | 750K | $10.97 | 8+ qtrs | No change |
| 77 | Adicet Bio IncACET | — | 0.09% | $8.1M | 1.18M | $6.81 | 8+ qtrs | ▲ Added 25% |
| 78 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.07% | $6.7M | 333.33K | $20.04 | 8+ qtrs | No change |
| 79 | Corvus Pharmaceuticals IncCRVS | — | 0.07% | $6.6M | 450K | $14.63 | 1 qtr | New |
| 80 | Rani Therapeutics Holdings-ARANI | — | 0.07% | $6.2M | 8.5M | $0.7348 | 2 qtrs | No change |
| 81 | Equillium IncEQ | — | 0.07% | $6.2M | 3.1M | $2.00 | 1 qtr | New |
| 82 | Werewolf Therapeutics IncHOWL | — | 0.06% | $5.6M | 6.68M | $0.8326 | 8+ qtrs | No change |
| 83 | Macrogenics IncMGNX | — | 0.06% | $5.4M | 1.86M | $2.89 | 1 qtr | New |
| 84 | Maplight Therapeutics IncMPLT | — | 0.05% | $5M | 248.29K | $20.33 | 1 qtr | New |
| 85 | Palatin Technologies IncPTN | — | 0.01% | $1.2M | 70K | $17.42 | 2 qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 46.9% | $4.4B | 10 |
| Technology | 0.28% | $26.8M | 2 |
| No sector on file | 52.9% | $5B | 73 |
Questions and answers
What did Peter Kolchinsky own in Q1 2026?
RA Capital Management's 13F for Q1 2026 lists 85 positions worth $9.4B. The largest: ASND (24.9%), PCVX (7.1%), RYTM (6.1%), TYRA (5.0%), SION (4.2%).
What did Peter Kolchinsky buy in Q1 2026?
The largest purchases, by the shares bought at the quarter-end price the filing implies: SGP (new, $207.8M), ZLAB (new, $107.4M), SRPT (new, $84.9M), DNTH (added, $83.9M), Nuvalent Inc (added, $67M), WVE (added, $63.6M).
What did Peter Kolchinsky sell in Q1 2026?
The largest sales: Cidara Therapeutics Inc (sold out, $743.4M), Avidity Biosciences Inc (sold out, $623.3M), Arcellx Inc (sold out, $82.6M), BLTE (sold out, $69.2M), IVVD (sold out, $42.3M), MDLN (sold out, $14.1M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Mar 31, 2026 on May 15, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q1 2026: RA Capital Management 13F holdings”, data as of 15 May 2026. https://funkfolio.com/gurus/peter-kolchinsky/2026-q1
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Mar 31, 2026.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Mar 31, 2026, filed May 15, 2026. Changes compare share counts with the filing for Dec 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 8 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.